Guest Venuell Posted November 18, 2022 Report Share Posted November 18, 2022 Subtype classification and single and meta gene proliferation scores were predicted on an independent test set of 814 samples from the GEICAM 9906 clinical trial, a randomized Phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel 22 ivermectin for rosacea The study design assumed a dropout rate of 15 for the primary end point assessment time of 12 weeks after registration Quote Link to comment Share on other sites More sharing options...
Recommended Posts